1. Preface
1.1. Market Definition and Scope
1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
3.3.1. Top 15 Origins of Pipeline Drugs
3.3.2. Biological versus non-biological drugs as a % of pipeline
3.3.3. Ongoing rise of gene and cell therapy
4. Global Cell Analysis Market Analysis and Forecast, by End-user
4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
4.3.1. Biotechnology & Pharmaceutical Companies
4.3.2. Academia
4.3.3. Cosmetic Industry
4.3.4. Contract Research Organizations
4.3.5. Contract Development and Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
5.3.1. Oncology & Immune-oncology
5.3.1.1. Small Molecules
5.3.1.2. Protein-based Therapeutics
5.3.1.3. Cell Therapy
5.3.1.4. Nucleic Acid-based Drugs
5.3.2. Cardiovascular & Metabolic Diseases
5.3.2.1. Small Molecules
5.3.2.2. Protein-based Therapeutics
5.3.2.3. Cell Therapy
5.3.2.4. Nucleic Acid-based Drugs
5.3.3. Immunology
5.3.3.1. Small Molecules
5.3.3.2. Protein-based Therapeutics
5.3.3.3. Cell Therapy
5.3.3.4. Nucleic Acid-based Drugs
5.3.4. Rare Diseases
5.3.4.1. Small Molecules
5.3.4.2. Protein-based Therapeutics
5.3.4.3. Cell Therapy
5.3.4.4. Nucleic Acid-based Drugs
5.3.5. Neurological Diseases
5.3.5.1. Small Molecules
5.3.5.2. Protein-based Therapeutics
5.3.5.3. Cell Therapy
5.3.5.4. Nucleic Acid-based Drugs
5.3.6. Others
5.3.6.1. Small Molecules
5.3.6.2. Protein-based Therapeutics
5.3.6.3. Cell Therapy
5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2017-2031
6.3.1. Flow Cytometry
6.3.2. Image-based Cytometry
6.3.3. Biochemical Assays
6.3.4. Mass Spectrometry
7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Workplace, 2017-2031
7.3.1. Target Identification
7.3.2. Hit Generation & Lead Identification
7.3.3. Lead Optimization
7.3.4. In Vitro Preclinical Studies
7.3.5. In Vivo Preclinical Studies
7.3.6. Clinical Studies
8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region
8.1. Key Findings
8.2. Market Value Forecast, by Country/Region, 2017-2031
8.2.1. U.S.
8.2.2. Europe
8.2.3. China
8.2.4. Rest of the World
9. U.S. Cell Analysis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
9.2.1. Biotechnology & Pharmaceutical Companies
9.2.2. Academia
9.2.3. Cosmetic Industry
9.2.4. Contract Research Organizations
9.2.5. Contract Development and Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Oncology & Immune-oncology
9.3.1.1. Small Molecules
9.3.1.2. Protein-based Therapeutics
9.3.1.3. Cell Therapy
9.3.1.4. Nucleic Acid-based Drugs
9.3.2. Cardiovascular & Metabolic Diseases
9.3.2.1. Small Molecules
9.3.2.2. Protein-based Therapeutics
9.3.2.3. Cell Therapy
9.3.2.4. Nucleic Acid-based Drugs
9.3.3. Immunology
9.3.3.1. Small Molecules
9.3.3.2. Protein-based Therapeutics
9.3.3.3. Cell Therapy
9.3.3.4. Nucleic Acid-based Drugs
9.3.4. Rare Diseases
9.3.4.1. Small Molecules
9.3.4.2. Protein-based Therapeutics
9.3.4.3. Cell Therapy
9.3.4.4. Nucleic Acid-based Drugs
9.3.5. Neurological Diseases
9.3.5.1. Small Molecules
9.3.5.2. Protein-based Therapeutics
9.3.5.3. Cell Therapy
9.3.5.4. Nucleic Acid-based Drugs
9.3.6. Others
9.3.6.1. Small Molecules
9.3.6.2. Protein-based Therapeutics
9.3.6.3. Cell Therapy
9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
9.4.1. Flow Cytometry
9.4.2. Image-based Cytometry
9.4.3. Biochemical Assays
9.4.4. Mass Spectrometry
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
9.5.1. Target Identification
9.5.2. Hit Generation & Lead Identification
9.5.3. Lead Optimization
9.5.4. In Vitro Preclinical Studies
9.5.5. In Vivo Preclinical Studies
9.5.6. Clinical Studies
10. Europe Cell Analysis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
10.2.1. Biotechnology & Pharmaceutical Companies
10.2.2. Academia
10.2.3. Cosmetic Industry
10.2.4. Contract Research Organizations
10.2.5. Contract Development and Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
10.3.1. Oncology & Immune-oncology
10.3.1.1. Small Molecules
10.3.1.2. Protein-based Therapeutics
10.3.1.3. Cell Therapy
10.3.1.4. Nucleic Acid-based Drugs
10.3.2. Cardiovascular & Metabolic Diseases
10.3.2.1. Small Molecules
10.3.2.2. Protein-based Therapeutics
10.3.2.3. Cell Therapy
10.3.2.4. Nucleic Acid-based Drugs
10.3.3. Immunology
10.3.3.1. Small Molecules
10.3.3.2. Protein-based Therapeutics
10.3.3.3. Cell Therapy
10.3.3.4. Nucleic Acid-based Drugs
10.3.4. Rare Diseases
10.3.4.1. Small Molecules
10.3.4.2. Protein-based Therapeutics
10.3.4.3. Cell Therapy
10.3.4.4. Nucleic Acid-based Drugs
10.3.5. Neurological Diseases
10.3.5.1. Small Molecules
10.3.5.2. Protein-based Therapeutics
10.3.5.3. Cell Therapy
10.3.5.4. Nucleic Acid-based Drugs
10.3.6. Others
10.3.6.1. Small Molecules
10.3.6.2. Protein-based Therapeutics
10.3.6.3. Cell Therapy
10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
10.4.1. Flow Cytometry
10.4.2. Image-based Cytometry
10.4.3. Biochemical Assays
10.4.4. Mass Spectrometry
10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
10.5.1. Target Identification
10.5.2. Hit Generation & Lead Identification
10.5.3. Lead Optimization
10.5.4. In Vitro Preclinical Studies
10.5.5. In Vivo Preclinical Studies
10.5.6. Clinical Studies
10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
10.6.1. EU5
10.6.2. U.K.
10.6.3. Switzerland
10.6.4. Rest of Europe
11. China Cell Analysis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
11.2.1. Biotechnology & Pharmaceutical Companies
11.2.2. Academia
11.2.3. Cosmetic Industry
11.2.4. Contract Research Organizations
11.2.5. Contract Development and Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
11.3.1. Oncology & Immune-oncology
11.3.1.1. Small Molecules
11.3.1.2. Protein-based Therapeutics
11.3.1.3. Cell Therapy
11.3.1.4. Nucleic Acid-based Drugs
11.3.2. Cardiovascular & Metabolic Diseases
11.3.2.1. Small Molecules
11.3.2.2. Protein-based Therapeutics
11.3.2.3. Cell Therapy
11.3.2.4. Nucleic Acid-based Drugs
11.3.3. Immunology
11.3.3.1. Small Molecules
11.3.3.2. Protein-based Therapeutics
11.3.3.3. Cell Therapy
11.3.3.4. Nucleic Acid-based Drugs
11.3.4. Rare Diseases
11.3.4.1. Small Molecules
11.3.4.2. Protein-based Therapeutics
11.3.4.3. Cell Therapy
11.3.4.4. Nucleic Acid-based Drugs
11.3.5. Neurological Diseases
11.3.5.1. Small Molecules
11.3.5.2. Protein-based Therapeutics
11.3.5.3. Cell Therapy
11.3.5.4. Nucleic Acid-based Drugs
11.3.6. Others
11.3.6.1. Small Molecules
11.3.6.2. Protein-based Therapeutics
11.3.6.3. Cell Therapy
11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
11.4.1. Flow Cytometry
11.4.2. Image-based Cytometry
11.4.3. Biochemical Assays
11.4.4. Mass Spectrometry
11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
11.5.1. Target Identification
11.5.2. Hit Generation & Lead Identification
11.5.3. Lead Optimization
11.5.4. In Vitro Preclinical Studies
11.5.5. In Vivo Preclinical Studies
11.5.6. Clinical Studies
12. Rest of the World Cell Analysis Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by End-user, 2017-2031
12.2.1. Biotechnology & Pharmaceutical Companies
12.2.2. Academia
12.2.3. Cosmetic Industry
12.2.4. Contract Research Organizations
12.2.5. Contract Development and Manufacturing Organizations
12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
12.3.1. Oncology & Immune-oncology
12.3.1.1. Small Molecules
12.3.1.2. Protein-based Therapeutics
12.3.1.3. Cell Therapy
12.3.1.4. Nucleic Acid-based Drugs
12.3.2. Cardiovascular & Metabolic Diseases
12.3.2.1. Small Molecules
12.3.2.2. Protein-based Therapeutics
12.3.2.3. Cell Therapy
12.3.2.4. Nucleic Acid-based Drugs
12.3.3. Immunology
12.3.3.1. Small Molecules
12.3.3.2. Protein-based Therapeutics
12.3.3.3. Cell Therapy
12.3.3.4. Nucleic Acid-based Drugs
12.3.4. Rare Diseases
12.3.4.1. Small Molecules
12.3.4.2. Protein-based Therapeutics
12.3.4.3. Cell Therapy
12.3.4.4. Nucleic Acid-based Drugs
12.3.5. Neurological Diseases
12.3.5.1. Small Molecules
12.3.5.2. Protein-based Therapeutics
12.3.5.3. Cell Therapy
12.3.5.4. Nucleic Acid-based Drugs
12.3.6. Others
12.3.6.1. Small Molecules
12.3.6.2. Protein-based Therapeutics
12.3.6.3. Cell Therapy
12.3.6.4. Nucleic Acid-based Drugs
12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
12.4.1. Flow Cytometry
12.4.2. Image-based Cytometry
12.4.3. Biochemical Assays
12.4.4. Mass Spectrometry
12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
12.5.1. Target Identification
12.5.2. Hit Generation & Lead Identification
12.5.3. Lead Optimization
12.5.4. In Vitro Preclinical Studies
12.5.5. In Vivo Preclinical Studies
12.5.6. Clinical Studies
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/